Opinion|Videos|March 12, 2025
The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
Panelists discuss how recent data from KEYNOTE-671, AEGEAN, and CheckMate 77T reinforce neoadjuvant therapy’s efficacy in early-stage non–small cell lung cancer (NSCLC), showing consistent survival benefits. In contrast, adjuvant data remain conflicting, limiting its role. Neoadjuvant therapy should be prioritized, with adjuvant therapy reserved for select high-risk patients.
Advertisement
Video content above is prompted by the following:
- What are your perspectives on the latest efficacy, safety data, and recent approvals in early-stage NSCLC treatment, and how have these influenced your clinical practice?
- KEYNOTE-671: Wakelee H, et al. NEJM. 2023;389:491-503.
- AEGEAN: Heymach JV, et al. WCLC 2024. Abs OA13.03. (Approval August 2024)
- CheckMate 77T: Spicer J, et al. ESMO 2024. LBA50(Approval October 2024)
- Briefly comment on the conflicting data in the adjuvant setting and contrast that with the consistency demonstrated in the neoadjuvant setting, and discuss how you translate this into your clinical practice.
- Should neoadjuvant therapy be recommended for all patients who do not proceed directly to surgery?
- In which patients should adjuvant therapy be added, and what is the remaining role for adjuvant therapy alone?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
3
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
4
Long-Term and Novel ADC Data Dominate Top Gynecologic Cancer Abstracts at ESMO 2026
5